How does plasma L-FABP level correlate with cardiovascular disease risk in patients with chronic kidney disease, and can it serve as a reliable biomarker for risk stratification?”

Nehad Refat Ibrahim, National institute of urology and nephrology Cairo, EGYPTFollow
Ghadir Elsawy, National institute of urology and nephrology Cairo, EGYPT

Article Type

Original Study

Subject Area

Laboratory Medicine

Abstract

Chronic kidney disease (CKD) affects up to 10% of the global adult population, with cardiovascular disease (CVD) being a major concern. CKD patients face increased CVD-related morbidity and mortality. While the exact mechanisms linking CKD and CVD are complex, traditional risk factors (e.g., diabetes, hypertension) and nontraditional factors (e.g., inflammation, oxidative stress) play a role. Liver-type fatty acid-binding protein (L-FABP) is associated with lipid metabolism and kidney injury. Few studies suggest L-FABP as a potential biomarker for CVD risk in CKD patients, but further research is needed to fully understand its role. This study aims to explore the link between liver-type fatty acid-binding protein (L-FABP) and cardiovascular health. Their aim is to understand how plasma L-FABP levels relate to cardiovascular disease (CVD) risk in chronic kidney disease (CKD) patients. The study employs a case-control design, carefully selecting cases with confirmed CKD and documented cardiovascular events. Controls are matched based on age, sex, and CKD stage. The mean L-FABP level was 12.5 ± 3.2, with a median of 1.8 (interquartile range: 9.6–14.2) across the entire sample. Elevated L-FABP levels were significantly associated with both CKD patients with CVD (30 cases) and CKD patients without CVD (15 controls), totaling 45 patients. High L-FABP levels conferred a 3-fold increased risk of CVD compared to low L-FABP levels (OR = 3, 95% CI: 2.07–5.83). The chi-square test confirmed a strong link between high L-FABP and CVD (p-value = 0.0004). Additionally, age and gender analyses revealed varying associations, emphasizing the need for further research to explore underlying mechanisms and clinical implications. In conclusion, L-FABP plays a crucial role in CVD risk across different CKD subgroups. While age and gender influence this association, additional investigations are warranted to elucidate mechanisms and guide clinical management

IRB Number

IUN00023

Keywords

Liver-type fatty acid-binding protein L-FABP, Chronic kidney disease (CKD), cardiovascular disease risk, and biomarkers.

Recommended Citation

Ibrahim, Nehad Refat and Elsawy, Ghadir (2024) "How does plasma L-FABP level correlate with cardiovascular disease risk in patients with chronic kidney disease, and can it serve as a reliable biomarker for risk stratification?”," Journal of Medicine in Scientific Research: Vol. 8: Iss. 1, Article 11.
DOI: https://doi.org/10.59299/2537-0928.1412